特点 Feature | 说明 Description | 客户价值 Value |
Tissue-Protective EPO Mimetic 组织保护性EPO模拟物 | Selectively activates the innate repair receptor (IRR) complex to deliver EPO-like tissue protection without stimulating erythropoiesis or increasing hematocrit. 选择性激活先天修复受体（IRR）复合物，提供类似EPO的组织保护作用，但不刺激红细胞生成或增加红细胞压积。 | Avoids the cardiovascular and thrombotic risks associated with recombinant EPO therapy while preserving neuroprotective benefits. 避免重组EPO治疗相关的心血管和血栓风险，同时保留神经保护效益。 |
Neuropathic Pain Target 神经病理性疼痛靶点 | Demonstrated efficacy in Phase II trials for painful small fiber neuropathy and sarcoidosis-associated neuropathy through IRR-mediated nerve repair mechanisms. II期临床试验中显示对痛性小纤维神经病变和结节病相关神经病有效，通过IRR介导的神经修复机制发挥作用。 | Addresses a significant unmet medical need in diabetic and chemotherapy-induced peripheral neuropathy treatment. 满足糖尿病和化疗引起的周围神经病变治疗中重大未满足医疗需求。 |
Non-Hematopoietic Safety 非造血安全性 | Unlike full-length EPO, Cibinetide does not bind the classical EPOR homodimer, eliminating hematocrit elevation and related adverse events. 与全长EPO不同，西比尼迪不结合经典EPOR同源二聚体，消除红细胞压积升高和相关不良事件。 | Favorable safety profile supports outpatient administration and chronic use scenarios without hematologic monitoring. 良好的安全性特征支持门诊给药和慢性使用，无需血液学监测。 |
Novel Mechanism of Action 新颖作用机制 | First-in-class peptide targeting the IRR (EPOR/CD131 heterocomplex), representing a paradigm shift in tissue-protective therapeutics. 首个靶向IRR（EPOR/CD131异源复合物）的肽类药物，代表组织保护性治疗的范式转变。 | Strong intellectual property and differentiation potential for partners developing next-generation neuropathic pain therapies. 强大的知识产权和差异化潜力，适合开发下一代神经病理性疼痛疗法的合作伙伴。 |
Clinical Stage Validation 临床阶段验证 | Completed Phase II studies with positive efficacy signals in multiple neuropathic pain indications. 完成II期研究，在多种神经病理性疼痛适应症中显示积极疗效信号。 | De-risked development pathway with established clinical proof-of-concept for licensing and co-development opportunities. 已确立临床概念验证，降低开发风险，适合授权许可和合作开发机会。 |
GMP-Ready Supply GMP就绪供应 | Available from research-grade to GMP-compliant API with full CMC documentation, stability data, and validated analytical methods. 从研究级到GMP合规API均可提供，附带完整CMC文件、稳定性数据和经验证的分析方法。 | Supports seamless progression from preclinical studies through clinical trials to commercial manufacturing. 支持从临床前研究到临床试验再到商业化生产的无缝推进。 |
Integrated API Procurement 集成API采购 | Single-source supply of API, reference materials, and regulatory packages with full batch traceability and quality assurance. API、参考材料和法规文件包的单一来源供应，具备完整批次可追溯性和质量保证。 | Simplifies vendor management and accelerates development timelines for biotech and pharma partners. 简化生物技术公司和制药合作伙伴的供应商管理，加速开发时间表。 |